An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.

Authors :: Fiedler W
Montesinos P
Schliemann C
Middeke J
Vasu S
Scholz CW
Esteve J
Mondal S
Rüter B
Burkard U
Osswald A
Blum W
Source :: Haematologica [Haematologica] 2022 Dec 01; Vol. 107 (12), pp. 2977-2982. Date of Electronic Publication: 2022 Dec 01.
Publication Year :: 2022

Subjects :: Humans
Antibodies, Monoclonal, Humanized therapeutic use
Decitabine therapeutic use
Maximum Tolerated Dose
Sialic Acid Binding Ig-like Lectin 3
Leukemia, Myeloid, Acute drug therapy
Antineoplastic Combined Chemotherapy Protocols adverse effects

Full Text Access

Tools